Single-Particle Characterization of Nanoparticle Bioconjugates

纳米颗粒生物共轭物的单颗粒表征

基本信息

  • 批准号:
    9888384
  • 负责人:
  • 金额:
    $ 14.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-05-01 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

Nanoparticles play several roles in biomedical technology, including as imaging contrast agents, heat sources for photothermal therapy, and as drug delivery vehicles. In many of these applications, nanoparticles are functionalized with specific antibodies for targeting purposes. Ideally, antibodies would be distributed equally among the nanoparticles in a preparation and evenly distributed on each nanoparticle’s surface; however, this is an overly simplistic picture. In reality, there are likely to be variations in the number of antibodies per nanoparticle, their spatial distribution on the surface, and the degree to which their function is preserved. In order to characterize nanoparticle bioconjugates, and to design improved ones, the details of the surface functionalization must be better understood. The following two aims will pave the way towards this goal. (1) The distributions of the number of antibodies per nanoparticle within a nanoparticle preparation will be measured at the single-particle level using microwell array analysis, for both gold and polystyrene nanoparticles. (2) The spatial arrangement of antibodies on the surfaces of individual nanoparticles will be imaged using sub-diffraction-limited fluorescence microscopy. The preparation methods will be optimized to produce nanoparticles with uniform functionalization in terms of the number and spatial distribution of molecules on the surface. Characterizing and optimizing the surface functionalization is important for the development of nanoparticle-based therapies. Improving the uniformity and quality of antibody functionalization will lead to improved targeting. The project will be carried out in the Department of Physics and Astronomy at the University of Texas at San Antonio, which is one of the country’s largest designated Hispanic Serving Institutions. An important part of this SCORE project will be the training of Ph.D. students from groups historically underrepresented in the physical and health sciences, and the elevation of research at this growing institution.
纳米粒子在生物医学技术中发挥着多种作用,包括成像造影剂、热源

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and bioconjugation of alkanethiol-stabilized gold bipyramid nanoparticles.
  • DOI:
    10.1088/1361-6528/abe823
  • 发表时间:
    2021-03-09
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Abdul-Moqueet MM;Tovias L;Lopez P;Mayer KM
  • 通讯作者:
    Mayer KM
Multiphysics Modeling of Plasmonic Photothermal Heating Effects in Gold Nanoparticles and Nanoparticle Arrays.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kathryn Mayer其他文献

Kathryn Mayer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 14.7万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 14.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了